Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: Results of French Adjuvant Study Group 02 and 07 trials

Annals of Oncology

Volumn 17, Issue 1, 2006, Pages 65-73

  Namer, Moise ^a,k   Fargeot, P ^b   Roche H ^c   Campone, M ^d   Kerbrat, P ^e   Romestaing, P ^f   Monnier, A ^g   Luporsi, E ^h   Montcuquet, P ⁱ   Bonneterre, J ^j  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d CENTRE RENÉ GAUDUCHEAU   (France)

^e CENTRE EUGÈNE MARQUIS   (France)

^f Centre Hospitalier Jules Courmont   (France)

^g Centre Hospitalier General Andre Boulloche   (France)

^h CENTRE ALEXIS VAUTRIN   (France)

ⁱ Clinique Saint Vincent   (France)

^j CENTRE OSCAR LAMBRET   (France)

^k Département d'Oncologie Médicale   (France)

more..

Author keywords

Adjuvant therapy; Breast cancer; Epirubicin; Estrogen receptor positive; Node positive; Tamoxifen

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MITOXANTRONE; TAMOXIFEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BASAL CELL CARCINOMA; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARDIOGENIC SHOCK; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; EARLY CANCER; ENDOMETRIUM CANCER; FEMALE; FRANCE; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL TOXICITY; HEAD AND NECK CARCINOMA; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; INFECTION; KIDNEY CARCINOMA; LUNG CARCINOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOMA; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIVARIATE ANALYSIS; MYELOMA; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CARCINOMA; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RADIATION INJURY; RETROSPECTIVE STUDY; SARCOMA; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; THYROID CARCINOMA; TUMOR VOLUME; UTERINE CERVIX TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODES; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAMOXIFEN;

EID: 29844448448     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj022     Document Type: Article

References (34)

1. Bonadonna G, Valagussa P, Rossi A et al. Ten year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 1985; 5: 95-115.
2. Crowther D. Controlled adjuvant chemotherapy trials for breast cancer in the United Kingdom. In Jones SE, Salmon E (eds): Adjuvant Therapy of Cancer, 2nd edition. New York, NY: Grune and Stratton 1979; 237-244.
3. Rubens RD, Hayward JL, Knight RK et al, Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet 1983; 1: 839-843.
4. Senn HJ, Jungi WF, Amgwerd R. Chemo (immuno) therapy with CMF + BCG in node-negative and node-positive breast cancer. In Jones SE, Salmon E (eds): Adjuvant Therapy of Cancer, 3rd edition. New York, NY: Grune and Stratton 1981; 331-337.
5. Wolmark N, Fisher B. Adjuvant chemotherapy in stage II breast cancer: A brief overview of the NSABP clinical trials. World J Surg 1985; 9: 699-706.
6. Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet 1985; 1: 836-840.
7. Ludwig Breast Cancer Study Group. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1984; 1: 1256-1260.
8. Rose C, Thorpe SM, Andersen KW et al. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1985; 1: 16-19.
9. Palshof T, Mouridsen HT, Daehnfeldt JL. Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen breast cancer trials. Eur J Cancer 1980; Suppl 1: 183-187.
10. Pritchard KI, Meakin JW, Boyd NF et al. A randomized trial of adjuvant tamoxifen in postmenopausal women with axillary node-positive breast cancer. In Jones SE, Salmon E (eds): Adjuvant Therapy of Cancer, 4th edition. New York, NY: Grune and Stratton 1984; 339-347.
11. Ribeiro G, Swindell R, The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma - 7-yr results, Eur J Cancer Clin Oncol 1985; 21: 897-900.
12. Rose C, Thorpe SM, Mouridsen HT et al. Antiestrogen treatment of postmenopausal women with primary high risk breast cancer. Breast Cancer Res Treat 1983; 3: 77-84.
13. Wallgren A, Baral E, Cartensen J et al. Should adjuvant tamoxifen be given for several years in breast cancer? In Jones SE, Salmon E (eds): Adjuvant Therapy of Cancer, 4th edition. New York, NY: Grune and Stratton 1984; 331-337.
14. Kaufmann F, Maas H, Kubli F et al. Risk adapted adjuvant chemo-hormone therapy in operable nodal positive breast cancer. In Jones SE, Salmon E (eds): Adjuvant Therapy of Cancer, 4th edition. New York, NY: Grune and Stratton 1984; 369-378.
15. Pearson OH, Hubay CA, Marshall JS et al. Adjuvant endocrine therapy, cytotoxic chemotherapy and immunotherapy in stage II breast cancer: five-year results. Breast Cancer Res Treat 1983; 3 (Suppl): S61-S68.
16. Taylor SG 4th, Kalish LA, Olson JE et al. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: Three-year results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1985; 3: 144-154.
17. Wolmark N, Fisher B. Adjuvant tamoxifen and chemotherapy in stage II breast cancer: Interim findings from NSABP protocol B-09. World J Surg 1985; 9: 759-755.
18. Mouridsen HT. Anthracyclines in the treatment of early breast cancer. Drugs 1993; 45 (Suppl 2): 1-3.
19. Fumoleau P, Kerbrat P, Romestaing P et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 2003; 21: 298-305.
20. Namer M, Fumoleau P, Devaux E et al. Node-positive postmenopausal breast cancer patients: Six-year follow-up results of a randomized trial testing the role of hormonotherapy (HT), chemotherapy (CT), or combination. Proc Am Soc Clin Oncol 1996; 16: 78 (Abstr).
21. Fargeot P, Roche H, Kerbrat P et al. Disease-free survival advantage of chemoendocrine therapy vs tamoxifen alone in node-positive (N+), positive hormone-receptors (Hr+) operable postmenopausal breast cancer patients (Pts): Results of FASG-07 randomized trial. Proc Am Soc Clin Oncol 2000; 19: 332 (Abstr).
22. Snedecor GW, Cochran WG. Statistical Methods, 7th edition. Ames: Iowa State University Press 1980.
23. Duncan DB. P-tests and intervals for comparison suggested by the data. Biometrics 1975; 31: 339-359.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
25. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc [A] 1972; 135: 185-198.
26. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-202.
27. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19: 602-611.
28. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998; 352: 930-942.
29. Crivellari D, Bonedl M, Castiglione-Gertsch M et al, Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group trial VII. J Clin Oncol 2000; 18: 1412-1422.
30. Albain K, Barlow W, O'Malley F et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). San Antonio Breast Cancer Symposium 2004: 37 (Abstr).
31. Wils JA, Bliss JM, Coombes MG et al. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive post menopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group. J Clin Oncol 1999; 17: 1988-1998.
32. Fargeot P, Bonneterre J, Roche H et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol 2004; 22: 4622-4630.
33. Roché H, Fumoleau P, Spielmann M et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium 2004: 27 (Abstr).
34. Pico C, Martin M, Jara C et al. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: Randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Ann Oncol 2004; 15: 79-87.